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The Nottingham prognostic index (NPI), based on tumour size in breast, node involvement and Scarff–Bloom–Richardson (SBR)
grading, has been shown to constitute a definitive prognostic factor of primary operable breast cancer in the adjuvant setting. We
performed a retrospective study to evaluate the prognostic value of this index in 163 patients after neoadjuvant chemotherapy.
Secondly, we examined the influence on survival of a revised NPI, only based on residual tumour size in breast and SBR grading in 228
patients, and consequently called breast grading index (BGI). The prognostic value of these two indices was also evaluated by
replacing the SBR grade with the MSBR grade, a French modified SBR grading; the modified NPI (MNPI) and modified BGI (MBGI)
were, respectively, obtained in 153 and 222 patients. At a median follow-up of 9.3 years, survival was significantly related to these four
indices (Po0.001). Multivariate analysis revealed that MBGI was the only one which retained a prognostic influence on disease-free
survival (Po0.02). In conclusion, the ‘amount’ of residual tumour in breast and/or nodes, as defined by NPI and revised indices,
confers a determinant prognosis after neoadjuvant chemotherapy, inviting an alternative postsurgical treatment for a subgroup of
patients with a decreased survival.
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Selection of systemic adjuvant therapy is based on prognostic and
predictive factors; prognostic factors are measurements associated
with clinical outcome, whereas predictive factors are measure-
ments related with the degree of response to a specific therapy
(Adjuvant Therapy for Breast Cancer, 2000). Studies of prognostic
factors in breast cancer to provide information on the risk of
systemic recurrence and/or death after definitive primary therapy,
and predictive factors help to choose which therapy might be
particularly advantageous for the survival.
Many variables have been shown to correlate with prognosis of
patients with breast carcinoma; among the most useful are the
presence and number of axillary lymph-node metastasis, tumour
size and histological grade (Adjuvant Therapy for Breast Cancer,
2000). However, these classical factors have been described after
primary surgery and much less is known after primary
chemotherapy followed by surgery. The National Surgical Ad-
juvant Breast and Bowel Project (NSABP) B-18 trial showed that
neoadjuvant chemotherapy resulted in high rates of breast tumour
response, axillary nodal downstaging and increased rates of breast
preservation (Fisher et al, 1998). Moreover, some changes in
biological markers have been shown that may be related to tumour
response (Makris et al, 1999). Consequently, primary chemother-
apy could possibly modify the prognostic value of known
parameters. We have recently demonstrated that a complete
pathological response conferred a survival advantage in patients
with operable breast cancer after neoadjuvant chemotherapy
(Chollet et al, 2002); a decreased survival was associated with an
increasing number of nodes in these patients (Cure et al, 2002).
Finally, we showed that primary chemotherapy seemed to induce
some modifications in the Scarff–Bloom–Richardson (SBR)
grading and, subsequently, only postchemotherapy SBR grading
was an independent prognostic factor, whereas prechemotherapy
SBR grade could predict the response to neoadjuvant chemother-
apy (Amat et al, 2002).
In the present study, we examined the prognostic value of
residual tumour, assessed by tumour size, SBR grade and lymph-
node stage, after induction chemotherapy. The team of Notting-
ham City Hospital constructed a prognostic index based on these
three parameters in patients with primary operable breast cancer
(Haybittle et al, 1982). This index was subsequently validated and
called the Nottingham prognostic index (NPI) (Galea et al, 1992).
The NPI was used to define three subsets of patients with different
chances of dying from breast cancer. As opposed to the British
study, the Danish group used conventional axillary lymph-node
staging and SBR grade evaluated only in ductal carcinomas
(Balslev et al, 1994). Paradoxical data have been published
concerning the prognostic significance of the NPI ever since
(Sauerbrei et al, 1997; Sundquist et al, 1999; D’Eredita et al, 2001;
Malmstrom et al, 2001; Fredriksson et al, 2002). Moreover, the NPI
has not been evaluated in a neoadjuvant setting and, as for the SBR
grade, we could wonder if it retains its prognostic value after
primary chemotherapy.
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lThe purpose of this study was to apply the NPI to the
characteristics of residual tumour after primary treatment in
patients with operable breast cancer. Four indices have been
calculated, corresponding to the sum of the individual scores
concerning (i) tumour size, lymph-node status and SBR grade
(NPI); (ii) tumour size and SBR grade (that we called the Breast
grading index, BGI); (iii) tumour size, lymph-node status and
MSBR grade (modified NPI, MNPI) and (iv) tumour size and
MSBR grade (Modified BGI, MBGI).
PATIENTS AND METHODS
Patients and treatment modalities
Between 1982 and 2001, 451 patients were treated by six cycles at 21-
to 28-day intervals of neoadjuvant chemotherapy into five
prospective phase II trials (Table 1), previously published (Belem-
baogo et al, 1992; Chollet et al, 1997, 2000; Van Praagh et al,2 0 0 1 ,
2002). The tumour size was 30mm in diameter or more, or was
situated in the central area of the nipple; all patients presented with
stage II–III operable breast cancer, according to the International
Union Against Cancer (UICC) recommendations (Sobin and
Wittekind, 1997). The diagnosis was usually established by fine-
needle aspiration or percutaneous microbiopsy of the primary
tumour and clinically involved axillary lymph nodes. The local
evaluation comprised clinical and echographic measurements of the
tumour and nodes, a bilateral mammography, a breast MRI in some
cases, and was repeated every two or three cycles of chemotherapy.
In all, 55 patients did not undergo surgery: 42 AVCF/M treated
by radiotherapy alone, three acute allergies to taxotere, six
progressions, two surgery refusals after clinical complete response
and two too early. Then, 396 patients were operated after six cycles
of treatment, by conservative surgery for good responders
(n¼280, 70.7%) and modified radical mastectomy (MRM) for
nonresponders (n¼116, 29.3%) (Table 2). Locoregional radio-
therapy was instituted within 6 weeks in 422 patients, and
additional courses of adjuvant chemotherapy were administered
to 100 patients with significant residual disease. Finally, 200
menopausal patients with hormonal receptor-positive tumours
received tamoxifen for 5 years.
Each patient was entered prospectively into the database and
was observed longitudinally. The complete medical records of all
patients were available for review at the time of this analysis.
Evaluation of the NPI and revised NPI (BGI)
The NPI was based on tumour size, lymph-node status and
histological grade (Balslev et al, 1994), as follows: NPI¼0.2 
tumour size (cm)þlymph-node stage (1, node-negative; 2, 1–3
positive lymph nodes; 3, X4 positive lymph nodes)þSBR grade
(1, good; 2, moderate; 3, poor).
These three parameters were evaluated in 163 out of the 451
patients, on needle core biopsies prospectively obtained when
possible, from residual tumour at surgery after primary che-
motherapy.
In order to identify a prognostic index, independent of axillary
nodes involvement, we constructed another score, by excluding the
parameter of lymph-node stage; it was called breast grading index
(BGI), and was determined in 228 patients as BGI¼0.2 tumour
size (cm)þSBR grade (1, good; 2, moderate, 3, poor).
Evaluation of the two modified scores from NPI and BGI
(MNPI and MBGI)
The prognostic value of the NPI was also evaluated according to
the modified SBR (MSBR) grading, obtained by ignoring the
degree of differentiation, as previously described (Le Doussal et al,
1989). The MNPI was obtained in 153 patients, as follows:
MNPI¼0.2 tumour size (cm)þlymph-node stage (1, node-
negative; 2, 1–3 positive lymph nodes; 3, X4 positive lymph
nodes)þMSBR grade (1–5).
Similarly, MBGI was calculated in 222 patients, as follows:
MBGI¼0.2 tumour size (cm)þMSBR grade (1–5).
Follow-up and survival
During the first 5 years of follow-up, patients had history and
physical examination, complete blood count, liver function tests,
serum CEA and CA 15-3 every 6 months. During the next 10 years,
patients had these clinical examinations and biology every 6
months, and mammography performed at yearly intervals.
The overall survival (OS) and disease-free survival (DFS) were
calculated from the date of diagnosis with the Kaplan–Meier
method (Kaplan and Meier, 1958); the cutoff date was 15 October
2002. The survival was analysed as a function of prognostic
indices. Three groups were defined for each index according to the
distribution of patients, as shown in Table 3. The log-rank statistic
test was used for univariate comparisons of survival end points
(Mantel, 1966). A stepwise Cox’s regression procedure (Cox, 1972)
was used to classify the NPI, BGI and modified scores among main
prognostic factors after neoadjuvant chemotherapy, that is, node
involvement, residual tumour size, SBR and MSBR grades. A P-
value of 0.05 or lower was considered statistically significant.
RESULTS
Study population
Table 2 lists the main characteristics of patients according to the
four indices evaluated (NPI, BGI, MNPI and MBGI). No significant
Table 1 Dosing for the five regimens used in phase II trials
Protocol Treatment
Every 4 weeks
AVCF/M
(n¼164 patients)
Doxorubicin D1 30mg/m
2
Vincristine D1 1mg/m
2
Cyclophosphamide D2–D5 300mg/m
2
Fluorouracil D2–D5 400mg/m
2
When methotrexate
is added
D2 and D4 20mg/m
2
Every 4 weeks
NEM
(n¼112 patients)
Vinorelbine/Navelbine
s D1 and D8 25mg/m
2
Epirubicin D1 and D8 35mg/m
2
Methotrexate D1 and D8 20mg/m
2
Every 3 weeks
Taxotere
(n¼86 patients)
Docetaxel/Taxotere
s 100mg/m
2
Every 3 weeks
TNCF
(n¼69 patients)
Theprubicin/THP-
adriamycin
s
D1–D3 20mg/m
2
Vinorelbine/ Navelbine
s D1 and D4 25mg/m
2
Cyclophosphamide D1–D4 300mg/m
2
Fluorouracil D1–D4 400mg/m
2
Every 3 weeks
NET
(n¼20 patients)
Vinorelbine/Navelbine
s D1 and D8 20mg/m
2
Epirubicin D1 and D8 35mg/m
2
Paclitaxel/Taxol
s D9 175mg/m
2
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ldifference was observed for patients and tumour characteristics
between these four groups. The median age of overall population
(n¼451) was 49 years (25–80) and 54.8% of women were
premenopausal. In all, 359 (79.6%) patients presented with
invasive ductal carcinoma. At diagnosis, there were 338 (74.9%)
stage II and 113 (25.1%) stage III tumours, with a median
tumour size of 4.0cm (1.5–13.0). At surgery, the residual
tumour size decreased to 1.5cm (0.0–8.0). Of these, 128 (46.2%)
patients did not have involved axillary node [pN0] at surgery
after initial chemotherapy; and 91 (32.9%) patients had more than
one and less than four positive nodes and 58 (20.9%) had four or
more nodes. After treatment, SBR grade divisions were 26.3%
grade I (14.7% at diagnosis), 52.1% grade II (49.8% at diagnosis)
and 21.6% grade III (35.5% at diagnosis). The MSBR grade at
surgery was 1 in 5.3%, 2 in 29.5%, 3 in 32.6%, 4 in 21.6% and 5 in
11.0% of tumours, whereas there were 3.0% grade 1, 23.9% grade 2,
33.0% grade 3, 24.3% grade 4 and 15.8% grade 5 tumours at
diagnosis.
Survival analysis
Univariate analysis After a median follow-up of 9.3 years, OS and
DFS were analysed as a function of NPI, BGI and modified scores
after neoadjuvant chemotherapy.
Table 2 Characteristics of patients treated by neoadjuvant chemotherapy in the overall population (n¼451), and in the population evaluated for NPI
(n¼163), BGI (n¼228), MNPI (n¼153) and MBGI (n¼222)
Population evaluated for
Characteristics Overall NPI BGI MNPI MBGI
Median age (years) 49.0 50.0 49.0 51.0 50.0
Characteristics at diagnosis Number of patients (%)
Menopausal status
Premenopausal 247 (54.8) 83 (50.9) 119 (52.2) 76 (49.7) 114 (51.3)
Menopausal 204 (45.2) 80 (49.1) 109 (47.8) 77 (50.3) 108 (48.7)
Stage
II 338 (74.9) 118 (72.4) 177 (77.6) 107 (69.9) 170 (76.6)
III 113 (25.1) 45 (27.6) 51 (22.4) 46 (30.1) 52 (23.4)
Pathology
Invasive ductal 359 (79.6) 142 (87.1) 198 (86.8) 125 (81.6) 181 (81.5)
Invasive lobular 55 (12.2) 4 (2.5) 6 (2.6) 14 (9.2) 20 (9.0)
Others 37 (8.2) 17 (10.4) 24 (10.6) 14 (9.2) 21 (9.5)
SBR grading
I 46 (14.7) 22 (17.2) 40 (22.0) 18 (15.4) 36 (21.2)
II 156 (49.8) 69 (53.9) 94 (51.7) 65 (55.5) 91 (53.5)
III 111 (35.5) 37 (28.9) 48 (26.3) 34 (29.1) 43 (25.3)
MSBR grading
1 9 (3.0) 5 (4.6) 7 (4.4) 5 (4.2) 8 (4.6)
2 71 (23.9) 23 (20.9) 43 (26.9) 31 (25.6) 53 (30.1)
3 98 (33.0) 43 (39.1) 59 (36.9) 46 (38.0) 65 (36.9)
4 72 (24.3) 28 (25.4) 34 (21.2) 27 (22.3) 33 (18.7)
5 47 (15.8) 11 (10.0) 17 (10.6) 12 (9.9) 17 (9.7)
Surgery n¼396 n¼163 n¼228 n¼153 n¼222
Conservative 280 (70.7) 101 (62.0) 159 (69.7) 99 (64.7) 158 (71.2)
MRM 116 (29.3) 62 (38.0) 69 (30.3) 54 (35.3) 64 (28.8)
Characteristics after treatment
Residual tumour size (cm) (range) 1.5 2.0 2.0 2.0 2.0
(0.0–8.0) (0.0–8.0) (0.0–8.0) (0.0–8.0) (0.0–8.0)
Axillary lymph node
0 128 (46.2) 57 (35.0) 55 (36.0)
1–3 91 (32.9) 65 (39.9) 58 (37.9)
X4 58 (20.9) 41 (25.1) 40 (26.1)
SBR grade
I 62 (26.3) 37 (22.7) 61 (26.7) 27 (19.9) 51 (25.6)
II 123 (52.1) 88 (54.0) 119 (52.2) 78 (57.3) 109 (54.8)
III 51 (21.6) 38 (23.3) 48 (21.1) 31 (22.8) 39 (19.6)
MSBR grading
1 12 (5.3) 5 (4.6) 7 (4.4) 5 (4.2) 8 (4.6)
2 67 (29.5) 23 (20.9) 43 (26.9) 31 (25.6) 53 (30.1)
3 74 (32.6) 43 (39.1) 59 (36.9) 46 (38.0) 65 (36.9)
4 49 (21.6) 28 (25.4) 34 (21.2) 27 (22.3) 33 (18.7)
5 25 (11.0) 11 (10.0) 17 (10.6) 12 (9.9) 17 (9.7)
Adjuvant treatment n¼442 n¼161 n¼226 n¼151 n¼220
Radiotherapy 422 (95.7) 156 (97.0) 219 (96.9) 147 (97.4) 214 (97.3)
Chemotherapy 100 (24.5) 42 (28.0) 58 (27.1) 39 (25.8) 57 (25.9)
Hormonotherapy 200 (46.3) 80 (51.3) 108 (49.3) 87 (57.6) 116 (52.7)
SBR¼Scarff–Bloom–Richardson grading in patients with invasive ductal carcinoma; MSBR¼modified SBR grading; MRM¼modified radical mastectomy. In each group, the
number of patients is not always equal to the total population due to the presence of certain nonmeasurable characteristics, withdrawal for drug allergies or toxicities. Moreover,
55 patients had not undergone surgery: 42 AVCF/M treated by radiotherapy alone, three acute allergies to taxotere, six progressions, two surgery refusals after clinical complete
response, two too early.
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lAs shown in Table 3, analysis of distribution showed that
patients were divided into three groups for each NPI. The median
values were 4.3 (2.2–7.6) for NPI, 2.4 (1.0–4.6) for BGI, 4.4 (2.1–
7.6) for MNPI and 3.4 (1.2–6.6) for MBGI. As shown in Table 3
and Figure 1, univariate analysis showed that the two NPI scores
evaluated according to SBR grade (NPI and BGI) were significantly
related with OS and DFS (Po0.001). Patients with an NPI o4o ra
BGI o2.2 had a better prognosis than others, with a 10-year OS of
91.2 and 84.6%, and a 10-year DFS of 65.3 and 63.0%, respectively.
Similarly, MNPI and MBGI seemed to have a high prognostic
influence on OS (Po0.001 and Po0.0003, respectively) and DFS
(Po0.003 and Po0.0002, respectively). Two excellent prognostic
groups were also underlined: subgroups with MNPI o3.9 and
MBGI o3 (Table 3 and Figure 2).
Multivariate analysis Multivariate analysis did not reveal any
prognostic factors of OS. Conversely, the MBGI appeared as the
most significant prognostic factor of DFS (Po0.02), with an eight-
Table 3 Survival analysis as a function of NPI and BGI scores after induction chemotherapy
No. of patients (%) 10-year OS (%) P-value at 10 years 10-year DFS (%) P-value at 10 years
NPI
[2.2–3.9] 54 (33.1) 91.2 65.3
[4.0–5.7] 91 (55.8) 55.5 0.0006 45.8 0.006
[5.8–7.6] 18 (11.1) 32.9 27.9
BGI
[1.0–2.1] 65 (28.5) 84.6 63.0
[2.2–3.3] 133 (58.3) 65.6 0.004 52.7 0.001
[3.4–4.6] 30 (13.2) 40.0 25.2
MNPI
[2.1–3.8] 50 (32.7) 91.3 60.1
[3.9–5.7] 81 (52.9) 56.7 0.0009 41.9 0.002
[5.8–7.6] 22 (14.4) 41.3 16.7
MBGI
[1.2–2.9] 75 (33.8) 92.2 67.6
[3.0–4.7] 119 (53.6) 61.8 0.0002 44.2 0.0001
[4.8–6.6] 28 (12.6) 39.0 25.6
OS¼overall survival; DFS¼disease-free survival.
NPI
Overall survival
= 0.2 × tumour size + lymph-node  
stage + SBR grade
= 0.2 × tumour size + SBR grade
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Figure 1 Univariate analysis of OS and DFS as a function of NPI based on SBR grading after neoadjuvant chemotherapy, with or without lymph-node
stage.
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lfold increased relative risk of death for patients with an MBGI
ranging from 4.8 to 6.6. Node involvement after neoadjuvant
chemotherapy was also correlated with DFS (Po0.03). All other
parameters considered, as SBR and MSBR grades, residual tumour
size or other NPI scores did not have prognostic significance on
DFS, probably due to the small number of patients in this
multivariate analysis (n¼182).
DISCUSSION
Several prognostic factors have been identified in breast cancer.
Among the most useful of these are the presence and number of
axillary lymph-node metastasis, tumour size, histological type and
SBR grade. The most powerful is indisputably the node involve-
ment with a prognosis inversely related to the number of involved
nodes, even after neoadjuvant chemotherapy and whatever the
treatment administered (Cameron et al, 1997; Pierga et al, 2000;
Cure et al, 2002). SBR grading is also by itself a prognostic
parameter; survival was worse in patients with poorly differen-
tiated tumours (grades II and III) compared with well-differen-
tiated grade I tumours (Simpson et al, 2000; Latinovic et al, 2001;
Amat et al, 2002). The tumour size in breast seems to be of lesser
significance. All these parameters are available (i) on pathological
examination at diagnosis; (ii) at surgery for the adjuvant setting; or
(iii) on residual tumour after neoadjuvant chemotherapy followed
by surgery.
Some studies showed the incidence and outcome of patients
with a pathological complete response (pCR) after neoadjuvant
chemotherapy (Machiavelli et al, 1998; Kuerer et al, 1999;
Chollet et al, 2002). Conversely, what is the role of residual
disease on survival in patients with operable breast cancer
after neoadjuvant chemotherapy? And how to express this
role? Our approach consisted of representing the ‘amount’ of
residual disease by collecting the three recognised prognostic
factors, that is, the node involvement, SBR grade and tumour size.
This combination constitutes a score called NPI, a reference index
of the literature (Haybittle et al, 1982; Galea et al, 1992; Balslev
et al, 1994). Originally designed with a special three nodes
dissection (Haybittle et al, 1982; Galea et al, 1992), it has been
converted into more conventional axillary dissection by the Danish
group (Balslev et al, 1992). In our study, we applied the NPI to
patients with operable breast cancer treated by neoadjuvant
chemotherapy, by incorporating or not the parameter of nodal
involvement (NPI and BGI). Moreover, the prognostic value of
these two indices was also evaluated by replacing the SBR grading
with the MSBR grading (MNPI and MBGI). This French
modification of the SBR grade retains five prognostic classes
instead of three (Le Doussal et al, 1989); MSBR grade, based on
nuclear pleomorphism and mitoses, can be determined in all
tumours, independent of the histological type, whereas the SBR
grade is only performed in invasive ductal carcinomas (Page, 1991;
Charpin et al, 1995).
Our results showed that the NPI score fully retained its
prognostic value after neoadjuvant chemotherapy, whatever the
modalities of calculation (Po0.001), that is, according to SBR
grading or MSBR grading, with or without the parameter of nodal
involvement. The division of prognostic groups, used in the
MNPI
= 0.2 × tumour size + lymph-node 
stage + MSBR grade
= 0.2 × tumour size + MSBR grade
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%
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Figure 2 Univariate analysis of OS and DFS as a function of NPI based on MSBR grading after neoadjuvant chemotherapy, with or without lymph-node
stage.
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lNottingham Study according to the NPI (i.e. good: NPI p3.4;
moderate: 3.4oNPIp5.4; and poor: NPI 45.4), was modified in
our study and realised according to the distribution of patients.
However, if we consider the Nottingham subgroups, the 10-year
survival rates are, respectively, 86.9, 62.9 and 40.5%, with a
P-value of 0.007 (data not shown). So, these value are nearly closed
to those of the Danish group, who, respectively, obtained 10-year
survival rates of 79.0, 55.9 and 24.7%. The minor difference
observed may be attributed to the benefit of adjuvant therapies,
especially for the poor prognostic group. Multivariate analysis
revealed that MBGI was the only one which retained a prognostic
influence on DFS (Po0.02). Its evaluation, based on tumour
size and MSBR grading, offers the advantage of identifying
patients with favourable prognosis, independent of the nodal
involvement.
In conclusion, in addition to pCR, the residual tumour assessed
by tumour size in the breast, SBR grading and nodal involvement
combined in NPI had a highly prognostic significance and
appeared to be applicable after neoadjuvant chemotherapy, as
well as in medically untreated tumours. These indices may offer a
useful practical value to evaluate the residual disease, and
subsequently to identify subgroups of patients with a better
prognosis. For these patients, it might be possible to avoid
adjuvant treatment in order to improve the quality of life.
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